As part of what probably will be the only major piece of health care legislation to get through Congress in a heated election year, House and Senate lawmakers in late June approved a plan to mandate early warnings from drugmakers about possible shortages of crucial medications.
The final bill to reauthorize the Prescription Drug User Fee Act, which contained the shortage provisions, largely satisfied members of organized medicine. Some physician organizations, however, had been pressing Congress to adopt stricter enforcement language and include biologic drugs in the early notification system that would alert federal officials of potential shortages.
Read the full story: http://tinyurl.com/84eawh9
Source: amednews.com
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis
August 5th 2025In this subanalysis of data from the ADjoin trial of lebrikizumab, the interleukin-13 receptor inhibitor that is also a monoclonal antibody showed itself to be effective over the long term in patients with atopic dermatitis on maintenance therapy.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More